

**SPECTRAL ANNOUNCES VOTING RESULTS OF ANNUAL MEETING**

**Toronto, Ontario, June 1, 2017** – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that at the annual meeting (the “Meeting”) of shareholders of the Corporation (“Shareholders”) that was held yesterday, all six nominees for the board were elected, the voting results of which are as follows:

<b>Director</b>	<b>Number and percentage of common shares of the Corporation (“Shares”) represented in person or by proxy and entitled to vote at the Meeting that were voted FOR</b>	<b>Number and percentage of Shares represented in person or by proxy and entitled to vote at the Meeting that were WITHELD from voting</b>
Paul M. Walker	116,834,763 (99.86%)	159,460 (0.14%)
Anthony Bihl III	116,816,363 (99.85%)	177,860 (0.15%)
Kevin Giese	116,551,452 (99.62%)	442,771 (0.38%)
Guillermo Herrera	116,816,009 (99.85%)	178,214 (0.15%)
William Stevens	116,834,863 (99.86%)	159,360 (0.14%)
Masayuki Kaneko	116,816,009 (99.85%)	178,241 (0.15%)

Full details of the foregoing are contained in the Report of Voting Results for the Meeting which has been filed on Sedar at [www.Sedar.com](http://www.Sedar.com).

**About Spectral Medical Inc.**

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). The PMX cartridge is a therapeutic hemoperfusion device that removes endotoxin, which is a potent mediator of sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

The PMX cartridge is currently approved for therapeutic use in many countries outside of the United States and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for the PMX cartridge and, in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit [www.spectraldx.com](http://www.spectraldx.com).

**Forward-looking statements**

*Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the review of the data from the clinical trial, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.*

*The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.*

For further information, please contact:

Anthony Busiskas  
Executive Vice President and CFO  
Spectral Medical Inc.  
416-626-3233 ext. 2200  
[tbusiskas@spectraldx.com](mailto:tbusiskas@spectraldx.com)

Ali Mahdavi  
Capital Markets & Investor  
Relations  
416-962-3300  
[am@spinnakercmi.com](mailto:am@spinnakercmi.com)